Tirzepatide may be better if you: Need a medication available right now : Tirzepatide is FDA-approved and available today through clinics and pharmacies Are sensitive to GI side effects : Lower overall side effect rates at every dose level Want established safety data : Years of post-marketing surveillance data available Have insurance coverage : Mounjaro/Zepbound may be partially covered Prefer a simpler titration : Uniform 2.5 mg steps are predictable and easy to follow Are a first-time incretin user : Extensive prescriber experience means better clinical support Retatrutide may be better if you: Have significant fatty liver disease : Liver fat reduction of up to 86% is unmatched Need maximum weight loss : 28.7% at 68 weeks exceeds all other compounds Have plateaued on tirzepatide : The glucagon component offers a new mechanism Are focused on metabolic health beyond weight : Triple agonism impacts more metabolic pathways Can tolerate higher GI burden : More side effects but more results Can wait for FDA approval : Expected late 2026-2027 for regulated access Neither compound is appropriate if you: Have a personal or family history of medullary thyroid carcinoma Have multiple endocrine neoplasia syndrome type 2 Are pregnant or planning pregnancy Have a history of severe psychiatric reactions to incretin therapies Have pancreatitis history (use with extreme caution) For researchers still undecided, the semaglutide vs tirzepatide comparison page provides additional context on how dual agonists compare to single agonists
Branded versus compounded: a storage comparison Comparing storage requirements across different semaglutide products helps put the compounded version in context
The approach with retatrutide will likely be similar, but we won't have official guidance until it's approved
Also of concern is the loss of lean muscle mass that can occur during weight loss on the drug
This shift in consumer behavior reflects a broader desire for affordability, customization, and most importantly, licensed oversight, rather than just rapid results or commercial hype
What they found was that people who actively engage in regular body composition scanning while rapidly losing weight were more likely to manage and mitigate the lean mass portion of that weight loss.Compared to the SUSTAIN 8 trial participants on GLP-1s, BodySpec patients clearly are achieving more desirable outcomes from their weight loss
